Biolojic Design's AI-Designed Multibody TEV-325 Achieves Preclinical Milestone for Autoimmune Disease Treatment
Key Insights
Biolojic Design (search) earned a milestone payment from Teva as TEV-325 (search), an AI-designed multibody targeting IL-13 (search) and TSLP (search), achieved a preclinical milestone for treating TH2-driven inflammatory diseases (search).
TEV-325 (search) represents a novel multibody design that can bind to either IL-13 (search) or TSLP (search) cytokines, potentially adapting to different disease states in conditions like asthma (search) and atopic dermatitis (search).
The compound could become the second multibody and third AI-designed molecule from Biolojic's platform to enter clinical trials, with Teva planning to initiate clinical studies in 2027.
Biolojic Design (search) has achieved a significant preclinical milestone for TEV-325 (search) (formerly BD9), marking a breakthrough for AI-designed therapeutics in autoimmune disease (search) treatment. The biotechnology company announced it earned an additional milestone payment from collaboration partner Teva Pharmaceutical Industries Ltd. as the novel multibody targeting IL-13 (search) and thymic stromal lymphopoietin (search) (TSLP (search)) advanced through preclinical development.
TEV-325 (search) is being developed for the treatment of TH2-driven inflammatory diseases (search) such as asthma (search) and atopic dermatitis (search), representing the first AI-designed multibody in development for autoimmune conditions. Teva holds an exclusive license to develop and commercialize the compound globally.
Revolutionary Multibody Design
TEV-325 (search) represents a new class of antibody therapeutics designed using Biolojic's Multibody Platform. Unlike conventional antibodies, this multibody can execute multiple, complex functions while maintaining the advantages of a natural human IgG format. Each arm of TEV-325 can bind to either IL-13 (search) or TSLP (search), two cytokines expressed at different frequencies during various stages of autoimmune diseases.
This adaptive binding capability potentially allows TEV-325 (search) to adjust to each patient's disease state at different time points, offering advantages over both conventional antibodies and bi-specific antibodies, which have fixed binding profiles and cannot adapt to changes in a patient's condition.
Clinical Development Timeline
Yanay Ofran, PhD, CEO and founder of Biolojic Design (search), expressed enthusiasm about the progress: "We're excited that TEV-325 (search) continues to advance through preclinical development and look forward to Teva's initiation of clinical trials targeted for 2027. TEV-325 is our first multibody in development for autoimmune disease (search) and, if it progresses, could become the second multibody and third AI-designed molecule from our platform to enter clinical trials."
The milestone reflects Biolojic's position at the forefront of AI-driven drug design. According to Ofran, "These assets illustrate how AI can solve clinical problems that other technologies have been struggling with for years."
Partnership Structure
Under the collaboration agreement, Teva is responsible for developing TEV-325 (search) and holds exclusive rights to develop, manufacture, and globally commercialize the compound. In return, Biolojic is eligible to receive milestone payments based on achieving specific preclinical, clinical, regulatory, and commercial milestones, along with royalty payments.
The company's platform has already generated the first AI-designed antibody to enter clinical trials, which is currently in phase 2 studies. Biolojic's technology transforms human antibodies into multifunctional, programmable switches with specific functions including agonism, antagonism, and conditional binding, enhancing both functionality and precision of therapeutic effects.